- Home
- FDMT vs JRVR Comparison
FDMT vs JRVR Comparison
Compare FDMT & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- JRVR
- Stock Information
- Founded
- FDMT 2013
- JRVR 2002
- Country
- FDMT United States
- JRVR Bermuda
- Employees
- FDMT N/A
- JRVR N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- JRVR Property-Casualty Insurers
- Sector
- FDMT Health Care
- JRVR Finance
- Exchange
- FDMT Nasdaq
- JRVR Nasdaq
- Market Cap
- FDMT 268.6M
- JRVR 241.0M
- IPO Year
- FDMT 2020
- JRVR 2005
- Fundamental
- Price
- FDMT $4.67
- JRVR $4.83
- Analyst Decision
- FDMT Buy
- JRVR Buy
- Analyst Count
- FDMT 11
- JRVR 5
- Target Price
- FDMT $41.70
- JRVR $10.40
- AVG Volume (30 Days)
- FDMT 1.1M
- JRVR 349.8K
- Earning Date
- FDMT 02-27-2025
- JRVR 02-26-2025
- Dividend Yield
- FDMT N/A
- JRVR 3.32%
- EPS Growth
- FDMT N/A
- JRVR N/A
- EPS
- FDMT N/A
- JRVR N/A
- Revenue
- FDMT $17,000.00
- JRVR $796,817,000.00
- Revenue This Year
- FDMT N/A
- JRVR N/A
- Revenue Next Year
- FDMT $159.49
- JRVR $7.46
- P/E Ratio
- FDMT N/A
- JRVR N/A
- Revenue Growth
- FDMT N/A
- JRVR 19.38
- 52 Week Low
- FDMT $4.48
- JRVR $4.35
- 52 Week High
- FDMT $36.25
- JRVR $11.49
- Technical
- Relative Strength Index (RSI)
- FDMT 32.64
- JRVR 52.98
- Support Level
- FDMT $4.68
- JRVR $4.54
- Resistance Level
- FDMT $5.15
- JRVR $4.84
- Average True Range (ATR)
- FDMT 0.41
- JRVR 0.12
- MACD
- FDMT -0.05
- JRVR 0.02
- Stochastic Oscillator
- FDMT 8.69
- JRVR 69.05
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure. and the Corporate and other segment consists of the management and treasury activities of holding companies, equity compensation for the group.